{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21
  ],
  "modelUsed": "gemini-2.5-pro",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Arm A: Palbociclib + Fulvestrant",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Patients receive palbociclib 125 mg/day orally for 3 weeks followed by 1 week off, plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and every 28 days thereafter."
      },
      {
        "id": "arm_2",
        "name": "Arm B: Placebo + Fulvestrant",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Patients receive placebo orally daily for 3 weeks followed by 1 week off, plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and every 28 days thereafter."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Pre-/peri-menopausal women",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who are pre- or peri-menopausal at study entry and receive the LHRH agonist goserelin in addition to their assigned randomized treatment."
      },
      {
        "id": "cohort_2",
        "name": "Post-menopausal women",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who are post-menopausal at study entry."
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 8,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator",
        "Caregiver",
        "Outcome Assessor"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "2:1"
      },
      "stratificationFactors": [
        "documented sensitivity to prior hormonal therapy (yes vs. no)",
        "menopausal status at study entry (pre-/peri- vs. post menopausal)",
        "presence of visceral metastases (yes vs. no)"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Oncology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator",
          "Caregiver",
          "Outcome Assessor"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "2:1",
        "stratificationFactors": [
          "documented sensitivity to prior hormonal therapy (yes vs. no)",
          "menopausal status at study entry (pre-/peri- vs. post menopausal)",
          "presence of visceral metastases (yes vs. no)"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Oncology"
      ]
    },
    "arms": [
      {
        "name": "Arm A: Palbociclib + Fulvestrant",
        "type": "Experimental Arm",
        "description": "Patients receive palbociclib 125 mg/day orally for 3 weeks followed by 1 week off, plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and every 28 days thereafter.",
        "isTitration": false
      },
      {
        "name": "Arm B: Placebo + Fulvestrant",
        "type": "Placebo Comparator Arm",
        "description": "Patients receive placebo orally daily for 3 weeks followed by 1 week off, plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and every 28 days thereafter.",
        "isTitration": false
      }
    ],
    "cohorts": [
      {
        "name": "Pre-/peri-menopausal women",
        "characteristic": "Patients who are pre- or peri-menopausal at study entry and receive the LHRH agonist goserelin in addition to their assigned randomized treatment."
      },
      {
        "name": "Post-menopausal women",
        "characteristic": "Patients who are post-menopausal at study entry."
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Occurs within 28 days prior to randomization to determine eligibility."
      },
      {
        "name": "Active Treatment Phase",
        "description": "Patients receive assigned treatment in 28-day cycles until objective progressive disease, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "name": "End of Treatment/Withdrawal",
        "description": "Visit performed no later than 4 weeks from the last dose of investigational products."
      },
      {
        "name": "Post-Treatment Follow-Up",
        "description": "Survival and new anti-cancer therapy information collected every 3 months after treatment discontinuation."
      }
    ]
  }
}